Bristol-Myers Squibb Reports Strong Fourth Quarter and Full-Year 2024 Results

Details

GAAP EPS was $0.04 in Q4 and a loss of $(4.41) for the full year, driven by acquired IPRD charges and licensing income. Non-GAAP EPS was $1.67 in Q4 and $1.15 for the full year. The company reported significant growth in its Growth Portfolio and provided 2025 guidance with expected revenues of approximately $45.5 billion, reflecting the impact of generics and foreign exchange. Additionally, BMY announced multiple regulatory approvals and clinical milestones for its products. A detailed presentation and earnings call were made available for further discussion.

Items reported

Exhibits (2)

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.